°Ë»ö
ä¿ë
Á¤º¸
    ÃÖ±Ù 2³â»õ ¸é´ë¾à±¹ ȯ¼ö °áÁ¤¾× »ç¹«À庴¿ø ³Ñ¾î¼­
    ±â»çÀÔ·Â : 24.05.20 05:58:55
    2 °¡
    ÇÃÄ£Ãß°¡
    À۳⠺ҹý°³¼³ ¾à±¹ ȯ¼ö¾× 1484¾ï¿ø...º´ÀÇ¿ø 1035¾ï¿ø

    ¸é´ë¾à±¹ ¡¼öÀ² 6.15% ±×ÃÄ¡¦Àç»êÀº´Ð¡¤Æó¾÷À¸·Î ȯ¼ö ¾î·Á¿ö


    [µ¥Àϸ®ÆÊ=ÀÌŹ¼ø ±âÀÚ] ÃÖ±Ù 2³â°£ ºÒ¹ý°³¼³(¸éÇã´ë¿©, ¸é´ë) ¾à±¹ ȯ¼ö °áÁ¤¾×ÀÌ ÀÇ·á±â°ü(»ç¹«À庴¿ø)À» ³Ñ¾î¼± °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

    ÀÌ´Â ±¹¹Î°Ç°­º¸Çè°ø´ÜÀÌ 2009³âºÎÅÍ ºÒ¹ý°³¼³ ±â°üÀ» ÇöÀå Á¶»çÇÑ ÀÌÈÄ Ã³À½ÀÌ´Ù. Ãֱ٠ȯ¼ö°¡ °áÁ¤µÈ ºÒ¹ý°³¼³ ±â°üÀÌ ÁÙ¾îµç ¿µÇâÀÌ ¹Ý¿µµÈ Çö»óÀ¸·Î Ç®À̵ȴÙ.

    19ÀÏ °ø´Ü¿¡ µû¸£¸é À۳⠱޿©¾×ÀÌ È¯¼ö°áÁ¤µÈ ºÒ¹ý°³¼³ ¾à±¹Àº 19°÷À¸·Î ±Ý¾×¸¸ 1484¾ï¿ø¿¡ À̸¥´Ù.

    °°ÀºÇØ ºÒ¹ý°³¼³ ÀÇ·á±â°ü 45°÷ÀÇ ±Þ¿©È¯¼ö°¡ °áÁ¤µÆ´Ù. ȯ¼ö±Ý¾×Àº 1035¾ï¿øÀÌ´Ù. ±Ý¾×¸¸ µûÁö¸é ºÒ¹ý °³¼³ ¾à±¹ÀÌ º´¿øÀ» ¾ÕÁö¸¥´Ù.



     ¡ãÀÚ·á Á¦°ø : ±¹¹Î°Ç°­º¸Çè°ø´Ü


    ºÒ¹ý°³¼³ ¾à±¹ ȯ¼ö±Ý¾×ÀÌ º´¿øÀ» ¿ªÀüÇϱ⠽ÃÀÛÇÑ °Ç 2022³â ºÎÅÍÀÌ´Ù. 2022³â¿¡´Â ÀÇ·á±â°ü 19°÷(917¾ï¿ø), ¾à±¹ 14°÷(1065¾ï¿ø)¿¡ ȯ¼ö °áÁ¤ÀÌ ³»·ÁÁ³´Âµ¥, ±Ý¾×¿¡¼­ ¾à±¹ÀÌ º´¿øÀ» ¾Õ¼¹´Ù.

    ÇÕ°è·Î µûÁö¸é ºÒ¹ý °³¼³ ÀÇ·á±â°üÀÌ ¾à±¹À» Å©°Ô ¾ÕÁö¸¥´Ù. ÀÇ·á±â°üÀº 1492°÷(ȯ¼ö¾× 2Á¶5907¾ï¿ø), ¾à±¹Àº 225°÷(7855¾ï¿ø)ÀÌ ºÒ¹ý °³¼³ÀÌ È®ÀεŠȯ¼ö °áÁ¤ÀÌ ³»·ÁÁ³´Ù.

    ÇÏÁö¸¸ ¡¼öÇÏÁö ¸øÇÑ µ·¸¸ 3Á¶1427¾ï¿ø¿¡ ´ÞÇÑ´Ù. ¸é¾Ö¾à±¹ ¡¼öÀ²µµ 6.15% ±×Ä¡°í ÀÖ´Ù.

    ÀÌ´Â ¼ö»ç°¡ Áö¿¬µÇ°Å³ª ¹ý¿ø °áÁ¤ÀÌ ´Ê¾îÁ® ºÒ¹ý ´ç»çÀÚµéÀÌ Àç»êÀ» Àº´ÐÇϰųª ±â°üÀ» Æó¾÷Çϱ⠶§¹®À¸·Î Ç®À̵ȴÙ. °ø´ÜÀº ÀÌ¿¡ Ưº°»ç¹ý°æÂû±Ç Á¦µµ¸¦ ÅëÇØ Á÷Á¢ ¼ö»ç±ÇÀ» ´Þ¶ó°í ¿äûÇÏ°í ÀÖÁö¸¸, °³Á¤ ¹ý·üÀÌ ±¹È¸ ¹®ÅÎÀ» ³Ñ¾î¼­Áö ¸øÇÏ°í ÀÖ´Ù. °ø´ÜÀº 22´ë ±¹È¸¿¡¼­µµ °ø´Ü Ư»ç°æ µµÀÔÀ» ÃßÁøÇÒ ¿¹Á¤ÀÌ´Ù.

    °ø´Ü °ü°èÀÚ´Â "»ç¹ýó¸® ÀýÂ÷ °úÁ¤¿¡¼­ ºÒ¹ý°³¼³ ±â°ü ´ç»çÀÚµéÀÌ Àç»êÀ» Àº´ÐÇϰųª Áßµµ Æó¾÷ÇÏ´Â »ç·Ê°¡ ¸¹¾Æ ±Þ¿© ȯ¼ö°¡ ¾î·Á¿öÁø´Ù"¸é¼­ "°ø´ÜÀÌ ¼ö»ç±ÇÀÌ °¡Áø´Ù¸é ÀÚ±ÝÈ帧 ÃßÀûÀÌ °¡´ÉÇØÁ® ÀçÁ¤´©¼ö Â÷´ÜÀÌ ¿ëÀÌÇÏ°í, ¼ö»ç±â°£µµ ´ÜÃàµÇ´Â È¿°ú°¡ ÀÖÀ» °Í"À̶ó°í ¼³¸íÇß´Ù.
    ÀÌŹ¼ø ±âÀÚ(hooggasi2@dailypharm.com)
    ±ÛÀÚÅ©±â ¼³Á¤
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    • Çѱ¹¾Ï¿þÀÌ R&D ºÎ¼­ Technical Regulatory Analystä¿ë ¹Ù·Î°¡±â
    • Medical Information Associate ¹Ù·Î°¡±â
    • RA, PV µî °¢ ºÎ¹® ¸ðÁý ¹Ù·Î°¡±â
    • °Ç°­±â´É½ÄÇ° ¾à±¹À¯Åë ÀÚ¹®/Çмú ¾à»ç ¸ðÁý ¹Ù·Î°¡±â
    • [Çѵ¶] RA/CRA(°è¾àÁ÷)/°Ç°­±â´É½ÄÇ° ¿¬±¸¿ø/HSE ÆÀÀå/IT º¸¾È ´ã´ç/°ü¸®¾à»ç/Corporate Development ¹Ù·Î°¡±â
    • External Engagement Partner ¹Ù·Î°¡±â
    • R&DºÎ¼­ °æ·ÂÁ÷ ¾à»ç¸ðÁý (¼­¿ïÁö»ç) ¹Ù·Î°¡±â
    • ¤·¤·
      ´ë°¡¸®°¡ ½âÀ¸´Ï ¹Ì·¡°¡ ¾ø´Ù
      ½Ç½À»ý ¼¼¿öµÎ°í ³î·¯´Ù´Ï´Â ±¹Àåµµ ¾î¶»°Ô ¸øÇÏ´Â ¼¼»óÀÌ´Ù
      24.05.20 14:47:57
      0 ¼öÁ¤ »èÁ¦ 1 0
    • Á¤¾à
      Áö¶ö³µ³×
      ¾à»çȸ ¸ð¸¦¸®°¡ ¾ø´Âµ¥
      ´ëÃæ ½¬½¬ÇÏ°í ó³Ñ±â´Ï
      µ¿¾÷¾à±¹ÀÌ´Ï ¸Ó´ÏµÇµµ¾ÈÇÑ°Ô ¼³Ä¡Áö
      À̲˱ú¹°°í ¸ð¸¥Ã´ÇÏ´Â ½Î°³ ´Ïµé¾à±¹ºÎÅÍ
      Ä¡µé½Î°³µéÀÌ È°°³Ä¡±æ ¹Ù¶õ´Ù
      24.05.20 09:21:00
      0 ¼öÁ¤ »èÁ¦ 3 1
    0/300
     
    ¸ÞÀϺ¸³»±â
    ±â»çÁ¦¸ñ : ÃÖ±Ù 2³â»õ ¸é´ë¾à±¹ ȯ¼ö °áÁ¤¾× »ç¹«À庴¿ø ³Ñ¾î¼­